Magistrate Judge Schneider of the District of New Jersey granted plaintiff Supernus’s motion to compel thirty-three documents that defendant TWi claimed were inadvertently produced privileged documents. The documents at issue concern defendant’s testing of the solubility of the active ingredient oxcarbazepine in the presence of certain excipients
On July 11, 2016, the U.S. Court of Appeals for the Federal Circuit—sitting en banc—issued a unanimous decision in The Medicines Company v. Hospira Inc., Case No. 14-1469, affirming that The Medicines Company’s use of contract manufacturing services did not invalidate U.S. Patent Nos. 7,582,727 and 7,598,343 (the “patents-in-suit”) under the on-sale bar. The patents-in-suit are listed in the FDA’s Orange Book as covering The Medicines Company’s drug product, Angiomax®, which is indicated for use as an anticoagulant during coronary angioplasty procedures.